The President of Inovalon (NASDAQ: INOV) is Buying Shares

By Carrie Williams

Today, the President of Inovalon (NASDAQ: INOV), Robert Wychulis, bought shares of INOV for $15.56K.

This recent transaction increases Robert Wychulis’ holding in the company by 5.36%. In addition to Robert Wychulis, 3 other INOV executives reported Buy trades in the last month.

The company has a one year high of $20.05 and a one year low of $8.60. INOV’s market cap is $1.4B and the company has a P/E ratio of 32.41. Currently, Inovalon has an average volume of 2.14M.

Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $15.80, reflecting a -39.6% downside. Seven different firms, including Goldman Sachs and KeyBanc, currently also have a Buy rating on the stock.

The insider sentiment on Inovalon has been positive according to 36 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

Inovalon Holdings, Inc. operates as a technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and improvement in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Its platform drives impact, improving quality and economics for health plans, hospitals, physicians, patients, pharmaceutical companies, and researchers. Inovalon Holdings was founded on September 11, 2014 and is headquartered in Bowie, MD.